Novel Strategies Incorporating Arsenic Trioxide into the Initial Treatment of Acute Promyelocytic Leukemia (APL)


Novel Strategies Incorporating Arsenic Trioxide into the Initial Treatment of Acute Promyelocytic Leukemia (APL)
Slides from presentations at ASH 2010 and transcribed comments from a recent interview with B Douglas Smith, MD (1/4/11)
Ades L et al. Arsenic trioxide (ATO) in the consolidation treatment of newly diagnosed APL — First interim analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL Group. Proc ASH 2010;Abstract 505.
 

Ravandi F et al. Phase II study of all-trans retinoic acid (ATRA), arsenic trioxide (ATO), with or without gemtuzumab ozogamicin (GO) for the frontline therapy of patients with acute promyelocytic leukemia (APL). Proc ASH 2010;Abstract 1080.

Dr Smith is Associate Professor of Oncology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland.